The deubiquitinase A20 in immunopathology of autoimmune diseases

Autoimmunity

Volumn 47, Issue 5, 2014, Pages 307-319

  Majumdar, Ishani ^a   Paul, Jaishree ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Deubiquitination; Dysregulated A20; Inflammation; Negative regulation; NF B

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DEUBIQUITINASE; DEUBIQUITINASE A20; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; MICRORNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; SIGNAL PEPTIDE;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DEUBIQUITINATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; FACIAL EXPRESSION; GENE LOCUS; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION INITIATION; UBIQUITINATION; ANIMAL; AUTOIMMUNITY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; MOUSE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-KAPPA B; POLYMORPHISM, GENETIC; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84904068775     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.900756     Document Type: Review

References (113)

1. Ahn, K. S., and B. B. Aggarwal. 2005. Transcription Factor NF-kB: A sensor for smoke and stress signals. Ann. New York Acad. Sci. 1056 218-233 (Pubitemid 43030980)
2. Shembade, N., and E. W. Harhaj. 2012. Regulation of NF-kB signaling by the A20 deubiquitinase. Cell Mol. Immunol. 9: 123-130.
3. Sun, S. C. 2008. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8: 501-511.
4. Dixit, V. M., S. Green, V. Sarma, et al. 1990. Tumor necrosis factoralpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 265: 2973-2978.
5. Verstrepen, L., K. Verhelst, G. van Loo, et al. 2010. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol. 80: 2009-2020.
6. Lee, E. G., D. L. Boone, S. Chai, et al. 2000. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 289: 2350-2354.
7. Komander, D., and D. Barford. 2008. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem. J. 409: 77-85.
8. Wertz, I. E., K. M. ORourke, H. Zhou, et al. 2004. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signaling. Nature. 430: 694-699. (Pubitemid 39061687)
9. Bosanac, I., I. E. Wertz, B. Pan, et al. 2010. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kB signaling. Mol Cell. 40: 548-557.
10. Tewari, M., F. W. Wolf, M. F. Seldin, et al. 1995. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J. Immunol. 154: 1699-1706.
11. ODonnell, M. A., D. Legarda-Addison, P. Skountzos, et al. 2007. Ubiquitination of RIP1 regulates an NF-kappaB-independent celldeath switch in TNF signaling. Curr. Biol. 17: 418-424.
12. Varfolomeev, E., T. Goncharov, A. V. Fedorova, et al. 2008. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J. Biol. Chem. 283: 24295-24299.
13. Lu, T. T., M. Onizawa, G. E. Hammer, et al. 2013. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity. 38: 896-905.
14. Li, L., N. Soetandyo, Q. Wang, and Y. Ye. 2009. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta. 1793: 346-353.
15. Shembade, N., A. Ma, and E. W. Harhaj. 2010. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science. 327: 1135-1139.
16. Skaug, B., J. Chen, F. Du, et al. 2011. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell. 44: 559-571.
17. Mauro, C., F. Pacifico, A. Lavorgna, et al. 2006. ABIN-1 binds to NEMO/IKK gamma and co-operates with A20 in inhibiting NF-kappaB. J. Biol. Chem. 281: 18482-18488. (Pubitemid 44035507)
18. Verhelst, K, I. Carpentier, M. Kreike, et al. 2012. A20 inhib LUBAC-mediated NF-kB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 31: 3845-3855.
19. Heyninck, K., and R. Beyaert. 1999. The cytokine-inducible zinc finger protein A20 inhibits IL-1- induced NF-kappaB activation at the level of TRAF6. FEBS Lett. 442: 147-150. (Pubitemid 29070823)
20. Wang, C., L. Deng, M. Hong, et al. 2001. TAK1 is a ubiquitindependent kinase of MKK and IKK. Nature. 412: 346-351. (Pubitemid 32694385)
21. Shi, C. S., and J. H. Kehrl. 2010. Traf6 and A20 differentially regulate TLR4-induced autophagy by affecting the ubiquitination of Beclin 1. Autophagy. 6: 986-987.
22. Inomata, M., S. Niida, K. Shibata, and T. Into. 2012. Regulation of Toll-like receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell Mol. Life Sci. 69: 963-979.
23. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533. (Pubitemid 37328672)
24. Hasegawa, M., Y. Fujimoto, P. C. Lucas, et al. 2008. A critical role of RICK/RIP2 poly-ubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27: 373-383. (Pubitemid 351161652)
25. Hitotsumatsu, O., R. C. Ahmad, R. Tavares, et al. 2008. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 28: 381-390. (Pubitemid 351343859)
26. Coornaert, B., M. Baens, K. Heyninck, et al. 2008. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 9: 263-271. (Pubitemid 351267323)
27. Düwel, M., V. Welteke, A. Oeckinghaus, et al. 2009. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitinchains. J. Immunol. 182: 7718-7728.
28. Chu, Y., J. C. Vahl, D. Kumar, et al. 2011. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation, hyperactivation, cause inflammation and autoimmunity in aged mice. Blood. 117: 2227-2236.
29. Ho, A. W., A. V. Garg, L. Monin, et al. 2013. The anaphasepromoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction. PLoS One. 8: e70168.
30. Garg, A. V., M. Ahmed, A. N. Vallejo, et al. 2013. The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci. Signal. 6: ra44.
31. Hutti, J. E., B. E. Turk, J. M. Asara, et al. 2007. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol. Cell Biol. 27: 7451-7461. (Pubitemid 350033652)
32. Shembade, N., R. Pujari, N. S. Harhaj, et al. 2011. The kinase IKKa inhibits activation of the transcription factor NF-kB by phosphorylating the regulatory molecule TAX1BP1. Nat. Immunol. 12: 834-843.
33. Lawrence, T., M. Bebien, G. Y. Liu, et al. 2005. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143. (Pubitemid 40663493)
34. Li, Q., Q. Lu, V. Bottero, et al. 2005. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc. Natl. Acad. Sci. USA. 102: 12425-12430. (Pubitemid 41266375)
35. Shirdel, E. A., W. Xie, T. W. Mak, and I. Jurisica. 2011. Navigating the micronome-using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS One. 6: e17429.
36. Zhao, J. L., D. S. Rao, M. P. Boldin, et al. 2011. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. USA. 108: 9184-9189.
37. Lu, Z., Y. Li, A. Takwi, et al. 2011. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 30: 57-67.
38. Song, L., C. Lin, H. Gong, et al. 2013. miR-486 sustains NF-kB activity by disrupting multiple NF-kB-negative feedback loops. Cell. Res. 23: 274-289.
39. Gantier, M. P., H. J. Stunden, C. E. McCoy, et al. 2012. A miR-19 regulon that controls NF-kB signaling. Nucl. Acids Res. 40: 8048-8058.
40. Kim, S. W., K. Ramasamy, H. Bouamar, et al. 2012. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Cell Mol. Immunol. 9: 123-130.
41. Trenkmann, M., M. Brock, R. E. Gay, et al. 2012. The TNFainduced miR-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-kB signaling. Arth. Rheum. doi: 10.1002.
42. Wang, C. M., Y. Wang, C. G. Fan, et al. 2011. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus related hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 411: 586-592.
43. Kulathu, Y., F. J. Garcia, T. E. Mevissen, et al. 2013. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat. Commun. 4: 1569.
44. Lin, X., and D. Wang. 2004. The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin. Immunol. 16: 429-435. (Pubitemid 39488023)
45. De Valck, D., K. Heyninck, W. Van Criekinge, et al. 1997. A20 inhibits NF- kappaB activation independently of binding to 14-3-3 proteins. Biochem. Biophys. Res. Commun. 238: 590-594. (Pubitemid 27464433)
46. Vincenz, C., and V. M. Dixit. 1996. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. J. Biol. Chem. 271: 20029-20034. (Pubitemid 26281752)
47. Musone, S. L., K. E. Taylor, J. Nititham, et al. 2011. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Gen. Immun. 12: 176-182.
48. Nair, R. P., K. C. Duffin, C. Helms, et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-B pathways. Nat. Genet. 41: 199-204.
49. Graham, R. R., C. Cotsapas, L. Davies, et al. 2008. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40: 1059-1061.
50. Lodolce, J. P., L. E. Kolodziej, and L. Rhee. 2010. African derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J. Immunol. 184: 7001-7009.
51. Kawasaki, A., I. Ito, S. Ito, et al. 2010. Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population. J. Biomed. Biotechnol. 2075-2078.
52. Musone, S. L., K. E. Taylor, T. T. Lu, et al. 2008. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 40: 1062-1064.
53. Adrianto, I., F. Wen, A. Templeton, et al. 2011. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 43: 253-258.
54. Thomson, W., A. Barton, X. Ke, et al. 2007. Rheumatoid arthritis association at 6q23. Nat. Genet. 39: 1431-1433. (Pubitemid 350191348)
55. Hughes, L. B., R. J. Reynolds, E. E. Brown, et al. 2010. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum. 62: 3547-3553.
56. Plenge, R. M., C. Cotsapas, L. Davies, et al. 2007. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 39: 1477-1482. (Pubitemid 350191346)
57. Zhernakova, A., E. A. Stahl, G. Trynka, et al. 2011. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 7: e1002004.
58. Bowes, J., R. Lawrence, S. Eyre, et al. 2010. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Hum. Genet. 128: 627-633.
59. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14 000 cases of seven common diseases and 3,000 shared controls. Nature. 447: 661-678.
60. Fung, E. Y., D. J. Smyth, J. M. Howson, et al. 2009. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes. Immun. 10: 188-191.
61. Chanudet, E., Y. Huang, K. Ichimura, et al. 2010. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia. 24: 483-487.
62. Jiang, X., H. Tian, Y. Fan, et al. 2012. Expression of tumor necrosis factor alpha-induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris. Clin. Vaccine Immunol. 19: 1938-1942.
63. Elsby, L. M., G. Orozco, J. Denton, et al. 2010. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin. Exp. Rheumatol. 28: 708-714.
64. Maxwell, J. R., I. R. Gowers, K. P. Kuet, et al. 2012. Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. Rheumatology. 51: 1514-1515.
65. Arsenescu, R., M. E. Bruno, E. W. Rogier, et al. 2008. Signature biomarkers in Crohns disease: toward a molecular classification. Muc. Immunol. 1: 399-411.
66. Zheng, C. F., and Y. Huang. 2011. Expression of zinc finger protein A20 in pediatric inflammatory bowel disease. Zhonghua Er Ke Za Zhi. 49: 261-265.
67. Abreu, M. T. 2010. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 10: 131-144.
68. Wang, J., Y. Guner, Y. Ouyang, et al. 2009. Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes. J. Immunol. 183: 1384-1392.
69. Turer, E. E., R. M. Tavares, E. Mortier, et al. 2008. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 205: 451-464. (Pubitemid 351281609)
70. Vereecke, L., M. Sze, C. Mc Guire, et al. 2010. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207: 1513-1523.
71. Niess, J. H. 2008. Role of mucosal dendritic cells in inflammatory bowel disease. W J. Gastrol. 14: 5138-5148.
72. Hammer, G. E., E. E. Turer, K. E. Taylor, et al. 2011. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat. Immunol. 12: 1184-1193.
73. Kolodziej, L. E., J. P. Lodolce, J. E. Chang, et al. 2011. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS One. 6: e26352. doi: 10.1371/journal.pone.0026352.
74. Lippens, S., S. Lefebvre, B. Gilbert, et al. 2011. Keratinocytespecific ablation of the NF-B regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death Differ. 18: 1845-1853.
75. Matmati, M., P. Jacques, J. Maelfait, et al. 2011. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 43: 908-912.
76. Kool, M., G. van Loo,W.Waelput, et al. 2011. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 35: 82-96.
77. Tavares, R. M., E. E. Turer, C. L. Liu, et al. 2010. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 33: 181-191.
78. Igarashi, H., A. Yahagi, T. Saika, et al. 2012. A pro-inflammatory role for A20 and ABIN family proteins in human fibroblast-like synoviocytes in rheumatoid arthritis. Immunol. Lett. 141: 246-253.
79. Yoon, H. K., H. S. Byun, H. Lee, et al. 2013. Intron-derived aberrant splicing of A20 transcript in rheumatoid arthritis. Rheumatology (Oxford). 52: 427-437.
80. Verstrepen, L., I. Carpentier, K. Verhelst, and R. Beyaert. 2009. ABINs: A20 binding inhibitors of NF- kappa B and apoptosis signaling. Biochem. Pharmacol. 78: 105-114.
81. Gateva, V., J. K. Sandling, G. Hom, et al. 2009. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genetics. 41: 1228-1233.
82. Kawasaki, A., S. Ito, H. Furukawa, et al. 2010. Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population: a case-control association study. Arthr. Res. Ther. 12: R174.
83. Callahan, J. A., G. E. Hammer, A. Agelides, et al. 2013. ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells. J. Immunol. 191: 535-539.
84. Zhou, J., R. Wu, A. A. High, et al. 2011. A20-binding inhibitor of NF-kB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein b activation and protects from inflammatory disease. Proc. Natl. Acad. Sci. U S A. 108: E998-E1006.
85. Nanda, S. K., R. K. Venigalla, A. Ordureau, et al. 2011. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J. Exp. Med. 208: 1215-1228.
86. Iha, H., J. M. Peloponese, L. Verstrepen, et al. 2008. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J. 27: 629-641. (Pubitemid 351273127)
87. Mc Guire, C., P. Wieghofer, L. Elton, et al. 2013. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J. Immunol. 190: 2896-2903.
88. Zhao, X., Y. Tang, B. Qu, et al. 2010. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 62: 3425-3435.
89. Sonkoly, E., T. Wei, P. C. Janson, et al. 2007. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2: e610.
90. Mestdagh, P., A. K. Bostrom, F. Impens, et al. 2010. The miR- 17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol. Cell. 40: 762-773.
91. Schmitt, M. J., C. Margue, I. Behrmann, and S. Kreis. 2013. MiRNA-29: a microRNA family with tumor-suppressing and immune modulating properties. Curr. Mol. Med. 13: 572-585.
92. Lindberg, R. L., F. Hoffmann, M. Mehling, et al. 2010. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsingremitting multiple sclerosis patients. Eur. J. Immunol. 40: 888-898.
93. Tufekci, K. U., M. G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and multiple sclerosis. Autoimmun. Dis. 2011: 807426.
94. Cox, M. B., M. J. Cairns, K. S. Gandhi, et al. 2010. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are underexpressed in MS whole blood. PLoS One. 5: e12132.
95. Nenci, A., C. Becker, A. Wullaert, et al. 2007. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 446: 557-561. (Pubitemid 46514732)
96. Piao, J. H., M. Hasegawa, B. Heissig, et al. 2011. Tumor necrosis factor receptor-associated factor (TRAF) 2 controls homeostasis of the colon to prevent spontaneous development of murine inflammatory bowel disease. J. Biol. Chem. 286: 17879-17888.
97. Lin, W. J., Y. W. Su, Y. C. Lu, et al. 2011. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkB2 signaling that contributes to autoimmunity. Proc. Natl. Acad. Sci. USA. 108: 18354-18359.
98. Shen, J., Y. Qiao, Z. Ran, and T. Wang. 2013. Different activation of TRAF4 and TRAF6 in inflammatory bowel disease. Mediators Inflamm. 647936.
99. Li, J., J. Tian, Y. Ma, et al. 2012. Association of RIP2 gene polymorphisms and systemic lupus erythematosus in a Chinese population. Mutagenesis. 27: 319-322.
100. Negroni, A., L. Stronati, M. Pierdomenico, et al. 2009. Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohns disease. Inflamm. Bowel Dis. 15: 1145-1154.
101. Hollenbach, E., M. Vieth, A. Roessner, et al. 2005. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem. 280: 14981-14988. (Pubitemid 40562850)
102. Shaw, P. J., M. J. Barr, J. R. Lukens, et al. 2011. Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity. 34: 75-84.
103. Hymowitz, S. G., and I. E. Wertz. 2010. A20: from ubiquitin editing to tumor suppression. Nat. Rev. Cancer. 10: 332-341.
104. Ungerbäck, J., D. Belenki, A. Jawad ul-Hassan, et al. 2012. Genetic variation and alterations of genes involved in NF-kB/TNFAIP3 and NLRP3 inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 33: 2126-2134.
105. Triantafillidis, J. K., G. Nasioulas, and P. A. Kosmidis. 2009. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 29: 2727-2737.
106. Shao, L., S. Oshima, B. Duong, et al. 2013. A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis. PLoS One. 8: e62223.
107. Tejasvi, T., P. E. Stuart, V. Chandran, et al. 2012. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J. Invest. Dermatol. 132: 593-600.
108. Hah, Y. S., Y. R. Lee, J. S. Jun, et al. 2010. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 62: 2313-2321.
109. Yu, L.Y., B. Lin, Z. L. Zhang, and L. H. Guo. 2004. Direct transfer of A20 gene into pancreas protected mice from streptozotocininduced diabetes. Acta Pharmacol. Sin. 25: 721-726. (Pubitemid 38736095)
110. Grey, S. T., C. Longo, T. Shukri, et al. 2003. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J. Immunol. 170: 6250-6256. (Pubitemid 36682610)
111. Scallon, B., A. Cai, N. Solowski, et al. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Therap. 301: 418-426. (Pubitemid 34429950)
112. Hage, C. A., K. L. Wood, H. T. Winer-Muram, et al. 2003. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 37: 838-840.
113. Gardam, M.A., E. C. Keystone, R. Menzies, et al. 2003. Antitumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Inf. Dis. 3: 148-55. (Pubitemid 36278124)